CRISPR, Recombinant DNA, and LAMP-Based Platforms for Monkeypox: Emerging Tools for Diagnosis and Therapeutic Development

Year : 2026 | Volume : 03 | Issue : 01 | Page : 7 28
    By

    Yukti Sabikhi,

  • Anshika Singh,

  • Sameen Masroor,

  • Chhavi Dudeja,

  • Sanya Kaushik,

  • Khushi Tyagi,

  1. Student, Jamia Hamdard University, Delhi, India
  2. Student, Jamia Hamdard University, Delhi, India
  3. Student, Jamia Hamdard University, Delhi, India
  4. Student, Jamia Hamdard University, Delhi, India
  5. Project Associate, CSIR- Institute of Genomics and Integrated Biology, Delhi, India
  6. Project Associate, CSIR- Institute of Genomics and Integrated Biology, Delhi, India

Abstract

Monkeypox, a zoonotic viral infection caused by the Monkeypox virus of the Orthopoxvirus genus, has recurred as a worldwide public health concern after recent outbreaks outside of its classical endemic areas in Central and West Africa. The resurgence has demanded a thorough reassessment of its epidemiology, mode of transmission, and clinical presentation. In light of these challenges, recombinant DNA technology (rDNA) has emerged as a candidate for developing vaccines, diagnostics, and therapeutic agents, as shown in the successful control of other viral diseases like hepatitis B and HPV. The combination of rDNA and CRISPR-based methods presents a revolutionary strategy for monkeypox surveillance and control. CRISPR-Cas systems—particularly Cas12a and Cas13a—have been shown to be effective for sensing MPXV with high sensitivity and specificity through fluorescence, lateral flow, and smartphone-based readouts. Challenges still exist in crRNA design, assay optimization, and standardization. Furthermore, Loop-mediated Isothermal Amplification (LAMP) directed against A27L and F3L genes of MPXV has shown encouraging sensitivity and specificity and was superior to traditional PCR approaches in some contexts. These diagnostic gains are matched by continued clinical trials for both conventional and emerging vaccine platforms—including MVA-BN, JYNNEOS, and RNA-based constructs such as BNT166a—and antiviral drugs like Tecovirimat. All the same, rapid diagnosis and availability of therapeutics remain significant challenges to monkeypox management. This review brings out the important contribution of new biotechnological tools, specifically rDNA, CRISPR, and LAMP, in revolutionizing existing diagnostic and treatment methods, hence leading to efficient disease management and future outbreak readiness.

Keywords: Monkeypox virus, Loop-mediated Isothermal Amplification (LAMP), CRISPR, Tecovirimat , recombinant DNA technology, assay optimization

[This article belongs to International Journal of Virus Studies ]

How to cite this article:
Yukti Sabikhi, Anshika Singh, Sameen Masroor, Chhavi Dudeja, Sanya Kaushik, Khushi Tyagi. CRISPR, Recombinant DNA, and LAMP-Based Platforms for Monkeypox: Emerging Tools for Diagnosis and Therapeutic Development. International Journal of Virus Studies. 2026; 03(01):7-28.
How to cite this URL:
Yukti Sabikhi, Anshika Singh, Sameen Masroor, Chhavi Dudeja, Sanya Kaushik, Khushi Tyagi. CRISPR, Recombinant DNA, and LAMP-Based Platforms for Monkeypox: Emerging Tools for Diagnosis and Therapeutic Development. International Journal of Virus Studies. 2026; 03(01):7-28. Available from: https://journals.stmjournals.com/ijvs/article=2026/view=237721


References

1. Nozaki, M. [Combined use of bucolome and pyrazolone derivatives (II). Complex formation due to interaction between bucolome and pyrazolones]. Nihon Yakurigaku Zasshi 1975, 71, 631–639. 2. Jamil, H.; Tariq, W.; Tahir, M.J.; Mahfooz, R.S.; Asghar, M.S.; Ahmed, A. Human Monkeypox Expansion from the Endemic to Non-Endemic Regions: Control Measures. Annals of Medicine & Surgery 2022, 79, doi:10.1016/j.amsu.2022.104048. 3. Gill, K.; Negi, S.; Rana, N.; Kumar, P. RDT and Genetic Engineering: Basic of RDT Method, PCR, and Application. In Basic Biotechniques for Bioprocess and Bioentrepreneurship; Elsevier, 2023; pp. 207–216 ISBN 978-0-12-816109-8. 4. Marzo, R.R. Bridging Borders: The Collective Fight against Monkeypox Outbreaks. In The Scientific Basis of Mpox (Monkeypox); Elsevier, 2025; pp. 75–100 ISBN 978-0-443-22123-1. 5. Nyame, J.; Punniyakotti, S.; Khera, K.; Pal, R.S.; Varadarajan, N.; Sharma, P. Challenges in the Treatment and Prevention of Monkeypox Infection; A Comprehensive Review. Acta Tropica 2023, 245, 106960, doi:10.1016/j.actatropica.2023.106960. 6. Durski, K.N.; McCollum, A.M.; Nakazawa, Y.; Petersen, B.W.; Reynolds, M.G.; Briand, S.; Djingarey, M.H.; Olson, V.; Damon, I.K.; Khalakdina, A. Emergence of Monkeypox — West and Central Africa, 1970–2017. MMWR Morb. Mortal. Wkly. Rep. 2018, 67, 306–310, doi:10.15585/mmwr.mm6710a5. 7. Mande, G.; Akonda, I.; De Weggheleire, A.; Brosius, I.; Liesenborghs, L.; Bottieau, E.; Ross, N.; Gembu, G.-C.; Colebunders, R.; Verheyen, E.; et al. Enhanced Surveillance of Monkeypox in Bas-Uélé, Democratic Republic of Congo: The Limitations of Symptom-Based Case Definitions. International Journal of Infectious Diseases 2022, 122, 647–655, doi:10.1016/j.ijid.2022.06.060. 8. VI. Epidemiology of Human Monkeypox. In Monographs in Virology; S. Karger AG, 1988; Vol. 17, pp. 81–110 ISBN 978-3-8055-4818-2. 9. Nakazawa, Y.; Emerson, G.L.; Carroll, D.S.; Zhao, H.; Li, Y.; Reynolds, M.G.; Karem, K.L.; Olson, V.A.; Lash, R.R.; Davidson, W.B.; et al. Phylogenetic and Ecologic Perspectives of a Monkeypox Outbreak, Southern Sudan, 2005. Emerg Infect Dis 2013, 19, 237–245, doi:10.3201/eid1902.121220. 10. Guarner, J.; Johnson, B.J.; Paddock, C.D.; Shieh, W.-J.; Goldsmith, C.S.; Reynolds, M.G.; Damon, I.K.; Regnery, R.L.; Zaki, S.R.; the Veterinary Monkeypox Virus Working Group Monkeypox Transmission and Pathogenesis in Prairie Dogs. Emerg. Infect. Dis. 2004, 10, 426–431, doi:10.3201/eid1003.030878. 11. Ogoina, D.; Damon, I.; Nakoune, E. Clinical Review of Human Mpox. Clinical Microbiology and Infection 2023, 29, 1493–1501, doi:10.1016/j.cmi.2023.09.004. 12. Galassi, F.M.; Sineo, L.; Papa, V.; Varotto, E. Monkeypox between Dermatology and Anthropology: A Model for Evolutionary Medicine. Clinics in Dermatology 2023, 41, 423–424, doi:10.1016/j.clindermatol.2023.04.001. 13. Saied, A.A. Is Monkeypox Virus Older than We Think? Transbounding Emerging Dis 2022, 69, 2407–2408, doi:10.1111/tbed.14651. 14. Happi, C.; Adetifa, I.; Mbala, P.; Njouom, R.; Nakoune, E.; Happi, A.; Ndodo, N.; Ayansola, O.; Mboowa, G.; Bedford, T.; et al. Urgent Need for a Non-Discriminatory and Non-Stigmatizing Nomenclature for Monkeypox Virus. PLoS Biol 2022, 20, e3001769, doi:10.1371/journal.pbio.3001769. 15. McInnes, C.J.; Damon, I.K.; Smith, G.L.; McFadden, G.; Isaacs, S.N.; Roper, R.L.; Evans, D.H.; Damaso, C.R.; Carulei, O.; Wise, L.M.; et al. ICTV Virus Taxonomy Profile: Poxviridae 2023: This Article Is Part of the ICTV Virus Taxonomy Profiles Collection. Journal of General Virology 2023, 104, doi:10.1099/jgv.0.001849. 16. Bryer, J.; Freeman, E.E.; Rosenbach, M. Monkeypox Emerges on a Global Scale: A Historical Review and Dermatologic Primer. Journal of the American Academy of Dermatology 2022, 87, 1069–1074, doi:10.1016/j.jaad.2022.07.007. 17. Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The Changing Epidemiology of Human Monkeypox—A Potential Threat? A Systematic Review. PLoS Negl Trop Dis 2022, 16, e0010141, doi:10.1371/journal.pntd.0010141. 18. Marennikova, S.S.; Seluhina, E.M.; Mal’ceva, N.N.; Ladnyj, I.D. Poxviruses Isolated from Clinically Ill and Asymptomatically Infected Monkeys and a Chimpanzee. Bull World Health Organ 1972, 46, 613–620. 19. Reed, K.D.; Melski, J.W.; Graham, M.B.; Regnery, R.L.; Sotir, M.J.; Wegner, M.V.; Kazmierczak, J.J.; Stratman, E.J.; Li, Y.; Fairley, J.A.; et al. The Detection of Monkeypox in Humans in the Western Hemisphere. N Engl J Med 2004, 350, 342–350, doi:10.1056/NEJMoa032299. 20. Di Giulio, D.B.; Eckburg, P.B. Human Monkeypox: An Emerging Zoonosis. The Lancet Infectious Diseases 2004, 4, 15–25, doi:10.1016/S1473-3099(03)00856-9. 21. Parker, S.; Nuara, A.; Buller, R.M.L.; Schultz, D.A. Human Monkeypox: An Emerging Zoonotic Disease. Future Microbiol. 2007, 2, 17–34, doi:10.2217/17460913.2.1.17. 22. Sklenovská, N.; Van Ranst, M. Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans. Front. Public Health 2018, 6, 241, doi:10.3389/fpubh.2018.00241. 23. Shuvo, P.A.; Roy, A.; Dhawan, M.; Chopra, H.; Emran, T.B. Recent Outbreak of Monkeypox: Overview of Signs, Symptoms, Preventive Measures, and Guideline for Supportive Management. International Journal of Surgery 2022, 105, 106877, doi:10.1016/j.ijsu.2022.106877. 24. León-Figueroa, D.A.; Bonilla-Aldana, D.K.; Pachar, M.; Romaní, L.; Saldaña-Cumpa, H.M.; Anchay-Zuloeta, C.; Diaz-Torres, M.; Franco-Paredes, C.; Suárez, J.A.; Ramirez, J.D.; et al. The Never-Ending Global Emergence of Viral Zoonoses after COVID-19? The Rising Concern of Monkeypox in Europe, North America and Beyond. Travel Med Infect Dis 2022, 49, 102362, doi:10.1016/j.tmaid.2022.102362. 25. Vaughan, A.; Aarons, E.; Astbury, J.; Brooks, T.; Chand, M.; Flegg, P.; Hardman, A.; Harper, N.; Jarvis, R.; Mawdsley, S.; et al. Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018. Emerg. Infect. Dis. 2020, 26, 782–785, doi:10.3201/eid2604.191164. 26. Akram, M.; Jabeen, F.; Daniyal, M.; Zainab, R.; Usman Ul Haq; Adetunji, C.O.; Egbuna, C.; Ephraim-Emmanuel, B.C.; Patrick-Iwuanyanwu, K.C.; Ogbo, A.B. Genetic Engineering of Novel Products of Health Significance: Recombinant DNA Technology. In Functional Foods and Nutraceuticals; Egbuna, C., Dable Tupas, G., Eds.; Springer International Publishing: Cham, 2020; pp. 595–611 ISBN 978-3-030-42318-6. 27. Mae-Wan Ho, Terje Traavik, Orjan Ol Gene Technology and Gene Ecology of Infectious Diseases. Microbial Ecology in Health and Disease 1998, 10, 33–59, doi:10.1080/089106098435421. 28. Snaith, R. Recombinant DNA Techniques: An Introduction. Biochemical Education 1984, 12, 187, doi:10.1016/0307-4412(84)90140-7. 29. Di Felice, F.; Micheli, G.; Camilloni, G. Restriction Enzymes and Their Use in Molecular Biology: An Overview. J Biosci 2019, 44, 38, doi:10.1007/s12038-019-9856-8. 30. Tabor, S. DNA Ligases. CP Molecular Biology 1989, 8, doi:10.1002/0471142727.mb0314s08. 31. Metanat, Y.; Viktor, P.; Amajd, A.; Kaur, I.; Hamed, A.M.; Abed Al-Abadi, N.K.; Alwan, N.H.; Chaitanya, M.V.N.L.; Lakshmaiya, N.; Ghildiyal, P.; et al. The Paths toward Non-Viral CAR-T Cell Manufacturing: A Comprehensive Review of State-of-the-Art Methods. Life Sciences 2024, 348, 122683, doi:10.1016/j.lfs.2024.122683. 32. Chance, R.E.; Frank, B.H. Research, Development, Production, and Safety of Biosynthetic Human Insulin. Diabetes Care 1993, 16, 133–142, doi:10.2337/diacare.16.3.133. 33. Johnston, C.; Martin, B.; Fichant, G.; Polard, P.; Claverys, J.-P. Bacterial Transformation: Distribution, Shared Mechanisms and Divergent Control. Nat Rev Microbiol 2014, 12, 181–196, doi:10.1038/nrmicro3199. 34. McGee, D.J.; Coker, C.; Harro, J.M.; Mobley, H.L. Bacterial Genetic Exchange. In Encyclopedia of Life Sciences; Wiley, 2001 ISBN 978-0-470-01617-6. 35. Ghosh, S.K.; Chatterjee, T. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Proteins (Cas) [CRISPR–Cas]: An Emerging Technique in Plant Disease Detection and Management. In Gene Editing in Plants; Kumar, A., Arora, S., Ogita, S., Yau, Y.-Y., Mukherjee, K., Eds.; Springer Nature Singapore: Singapore, 2024; pp. 589–645 ISBN 978-981-9985-28-9. 36. Dronina, J.; Samukaite-Bubniene, U.; Ramanavicius, A. Towards Application of CRISPR-Cas12a in the Design of Modern Viral DNA Detection Tools (Review). J Nanobiotechnol 2022, 20, 41, doi:10.1186/s12951-022-01246-7. 37. Xie, S.; Qin, C.; Zhao, F.; Shang, Z.; Wang, P.; Sohail, M.; Zhang, X.; Li, B. A DNA–Cu Nanocluster and Exonuclease I Integrated Label-Free Reporting System for CRISPR/Cas12a-Based SARS-CoV-2 Detection with Minimized Background Signals. J. Mater. Chem. B 2022, 10, 6107–6117, doi:10.1039/D2TB00857B. 38. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science 2012, 337, 816–821, doi:10.1126/science.1225829. 39. Dai, Y.; Wu, Y.; Liu, G.; Gooding, J.J. CRISPR Mediated Biosensing Toward Understanding Cellular Biology and Point‐of‐Care Diagnosis. Angew Chem Int Ed 2020, 59, 20754–20766, doi:10.1002/anie.202005398. 40. Chen, M.; Shafer-Peltier, K.; Randtke, S.J.; Peltier, E. Competitive Association of Cations with Poly(Sodium 4-Styrenesulfonate) (PSS) and Heavy Metal Removal from Water by PSS-Assisted Ultrafiltration. Chemical Engineering Journal 2018, 344, 155–164, doi:10.1016/j.cej.2018.03.054. 41. Liu, Z.; Liu, Y.; Liu, F.; Zhang, S.; Wang, X.; Lu, Q.; Wang, K.; Zhang, B.; Peng, R. Genome-Wide Survey and Comparative Analysis of Long Terminal Repeat (LTR) Retrotransposon Families in Four Gossypium Species. Sci Rep 2018, 8, 9399, doi:10.1038/s41598-018-27589-6. 42. Wang, L.; Xu, C.; Zhang, S.; Chen, S.; Wang, H.; Duan, Z.; Al-Hartomy, O.A.; Wageh, S.; Wen, X.; Liu, Y.; et al. Rapid and Ultrasensitive Detection of Mpox Virus Using CRISPR/Cas12b-Empowered Graphene Field-Effect Transistors. Applied Physics Reviews 2023, 10, 031409, doi:10.1063/5.0142494. 43. Singh, M.; Bindal, G.; Misra, C.S.; Rath, D. The Era of Cas12 and Cas13 CRISPR-Based Disease Diagnosis. Critical Reviews in Microbiology 2022, 48, 714–729, doi:10.1080/1040841X.2021.2025041. 44. Hueso, L.; Martorell, S.; Sena-Torralba, A.; Ferrando, M.; Ferri, M.; Maquieira, A.; Ntoumi, F.; Morais, S. Recombinase Polymerase Amplification Technology for Point-of-Care Diagnosis of Neglected Tropical Diseases. International Journal of Infectious Diseases 2025, 153, 107831, doi:10.1016/j.ijid.2025.107831. 45. Chen, Y.; Zhao, R.; Hu, X.; Wang, X. The Current Status and Future Prospects of CRISPR-Based Detection of Monkeypox Virus: A Review. Analytica Chimica Acta 2025, 1336, 343295, doi:10.1016/j.aca.2024.343295. 46. Chen, H.; Cheng, X.; Wang, Y.; Han, N.; Liu, L.; Wei, H.; Tu, Z.; Gu, Z.; Song, R.; Wang, S.; et al. Two-Dimensional Nanozyme-Catalyzed Colorimetric CRISPR Assay for the Microfluidic Detection of Monkeypox Virus. Anal. Chem. 2025, 97, 4407–4415, doi:10.1021/acs.analchem.4c05570. 47. Gootenberg, J.S.; Abudayyeh, O.O.; Kellner, M.J.; Joung, J.; Collins, J.J.; Zhang, F. Multiplexed and Portable Nucleic Acid Detection Platform with Cas13, Cas12a, and Csm6. Science 2018, 360, 439–444, doi:10.1126/science.aaq0179. 48. Patchsung, M.; Jantarug, K.; Pattama, A.; Aphicho, K.; Suraritdechachai, S.; Meesawat, P.; Sappakhaw, K.; Leelahakorn, N.; Ruenkam, T.; Wongsatit, T.; et al. Clinical Validation of a Cas13-Based Assay for the Detection of SARS-CoV-2 RNA. Nat Biomed Eng 2020, 4, 1140–1149, doi:10.1038/s41551-020-00603-x. 49. Tomita, N.; Mori, Y.; Kanda, H.; Notomi, T. Loop-Mediated Isothermal Amplification (LAMP) of Gene Sequences and Simple Visual Detection of Products. Nat Protoc 2008, 3, 877–882, doi:10.1038/nprot.2008.57. 50. Li, Y.; Tan, G.; Lan, P.; Zhang, A.; Liu, Y.; Li, R.; Li, F. Detection of Tobamoviruses by RT-PCR Using a Novel Pair of Degenerate Primers. Journal of Virological Methods 2018, 259, 122–128, doi:10.1016/j.jviromet.2018.06.012. 51. Zhou, Y.; Chen, Z. Mpox: A Review of Laboratory Detection Techniques. Arch Virol 2023, 168, 221, doi:10.1007/s00705-023-05848-w. 52. Feng, J.; Xue, G.; Cui, X.; Du, B.; Feng, Y.; Cui, J.; Zhao, H.; Gan, L.; Fan, Z.; Fu, T.; et al. Development of a Loop-Mediated Isothermal Amplification Method for Rapid and Visual Detection of Monkeypox Virus. Microbiol Spectr 2022, 10, e02714-22, doi:10.1128/spectrum.02714-22. 53. Hussein, M.H.; Mohamad, M.A.; Dhakal, S.; Sharma, M. Cellulitis or Lymphadenopathy: A Challenging Monkeypox Virus Infection Case. Cureus 2023, doi:10.7759/cureus.40008. 54. Adler, H.; Gould, S.; Hine, P.; Snell, L.B.; Wong, W.; Houlihan, C.F.; Osborne, J.C.; Rampling, T.; Beadsworth, M.B.; Duncan, C.J.; et al. Clinical Features and Management of Human Monkeypox: A Retrospective Observational Study in the UK. The Lancet Infectious Diseases 2022, 22, 1153–1162, doi:10.1016/S1473-3099(22)00228-6. 55. Berthet, N.; Descorps-Declère, S.; Besombes, C.; Curaudeau, M.; Nkili Meyong, A.A.; Selekon, B.; Labouba, I.; Gonofio, E.C.; Ouilibona, R.S.; Simo Tchetgna, H.D.; et al. Genomic History of Human Monkey Pox Infections in the Central African Republic between 2001 and 2018. Sci Rep 2021, 11, 13085, doi:10.1038/s41598-021-92315-8. 56. Ladnyj, I.D.; Ziegler, P.; Kima, E. A Human Infection Caused by Monkeypox Virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ 1972, 46, 593–597. 57. Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S.; et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. N Engl J Med 2022, 387, 679–691, doi:10.1056/NEJMoa2207323. 58. Sun, W.M.D. Monkeypox, Smallpox, FDA, and Accelerated Approval of Vaccines – A Regulatory Perspective. Vaccine 2023, 41, 3681–3682, doi:10.1016/j.vaccine.2023.05.008. 59. Yinka-Ogunleye, A.; Aruna, O.; Dalhat, M.; Ogoina, D.; McCollum, A.; Disu, Y.; Mamadu, I.; Akinpelu, A.; Ahmad, A.; Burga, J.; et al. Outbreak of Human Monkeypox in Nigeria in 2017–18: A Clinical and Epidemiological Report. The Lancet Infectious Diseases 2019, 19, 872–879, doi:10.1016/S1473-3099(19)30294-4. 60. Schnierle, B.S. Monkeypox Goes North: Ongoing Worldwide Monkeypox Infections in Humans. Viruses 2022, 14, 1874, doi:10.3390/v14091874. 61. Rahman, M.T.; Sobur, M.A.; Islam, M.S.; Ievy, S.; Hossain, M.J.; El Zowalaty, M.E.; Rahman, A.T.; Ashour, H.M. Zoonotic Diseases: Etiology, Impact, and Control. Microorganisms 2020, 8, 1405, doi:10.3390/microorganisms8091405. 62. Louten, J. Virus Transmission and Epidemiology. In Essential Human Virology; Elsevier, 2016; pp. 71–92 ISBN 978-0-12-800947-5. 63. Mims, C.A. The Origin of Major Human Infections and the Crucial Role of Person-to-Person Spread. Epidemiol. Infect. 1991, 106, 423–433, doi:10.1017/S0950268800067479. 64. Heskin, J.; Belfield, A.; Milne, C.; Brown, N.; Walters, Y.; Scott, C.; Bracchi, M.; Moore, L.S.; Mughal, N.; Rampling, T.; et al. Transmission of Monkeypox Virus through Sexual Contact – A Novel Route of Infection. Journal of Infection 2022, 85, 334–363, doi:10.1016/j.jinf.2022.05.028. 65. Ligon, B.L. Monkeypox: A Review of the History and Emergence in the Western Hemisphere. Seminars in Pediatric Infectious Diseases 2004, 15, 280–287, doi:10.1053/j.spid.2004.09.001. 66. Beer, E.M.; Rao, V.B. A Systematic Review of the Epidemiology of Human Monkeypox Outbreaks and Implications for Outbreak Strategy. PLoS Negl Trop Dis 2019, 13, e0007791, doi:10.1371/journal.pntd.0007791. 67. Brisse, M.E.; Hickman, H.D. Viral Infection and Dissemination Through the Lymphatic System. Microorganisms 2025, 13, 443, doi:10.3390/microorganisms13020443. 68. Islam, M.A.; Mumin, J.; Haque, M.M.; Haque, Md.A.; Khan, A.; Bhattacharya, P.; Haque, M.A. Monkeypox Virus (MPXV): A Brief Account of Global Spread, Epidemiology, Virology, Clinical Features, Pathogenesis, and Therapeutic Interventions. Infectious Medicine 2023, 2, 262–272, doi:10.1016/j.imj.2023.11.001. 69. Araf, Y.; Nipa, J.F.; Naher, S.; Maliha, S.T.; Rahman, H.; Arafat, K.I.; Munif, M.R.; Uddin, M.J.; Jeba, N.; Saha, S.; et al. Insights into the Transmission, Host Range, Genomics, Vaccination, and Current Epidemiology of the Monkeypox Virus. Veterinary Medicine International 2024, 2024, 8839830, doi:10.1155/2024/8839830. 70. Kadiyala, K.G.; Goutham, K.; Katari, N.K.; Vanipenta, Y. Vaccines, Diagnosis, and Treatment of Infectious Diseases. In Sustainable Nanomaterials for Treatment and Diagnosis of Infectious Diseases; Chokkareddy, R., Kanchi, S., Redhi, G.G., Eds.; Wiley, 2025; pp. 113–138 ISBN 978-1-394-20001-6. 71. Altindis, M.; Puca, E.; Shapo, L. Diagnosis of Monkeypox Virus – An Overview. Travel Medicine and Infectious Disease 2022, 50, 102459, doi:10.1016/j.tmaid.2022.102459. 72. Silva, S.J.R. da; Kohl, A.; Pena, L.; Pardee, K. Clinical and Laboratory Diagnosis of Monkeypox (Mpox): Current Status and Future Directions. iScience 2023, 26, 106759, doi:10.1016/j.isci.2023.106759. 73. Johri, N.; Kumar, D.; Nagar, P.; Maurya, A.; Vengat, M.; Jain, P. Clinical Manifestations of Human Monkeypox Infection and Implications for Outbreak Strategy. Health Sciences Review 2022, 5, 100055, doi:10.1016/j.hsr.2022.100055. 74. Yi, X.-M.; Lei, Y.-L.; Li, M.; Zhong, L.; Li, S. The Monkeypox Virus-Host Interplays. Cell Insight 2024, 3, 100185, doi:10.1016/j.cellin.2024.100185. 75. Wang, R.; Lan, C.; Benlagha, K.; Camara, N.O.S.; Miller, H.; Kubo, M.; Heegaard, S.; Lee, P.; Yang, L.; Forsman, H.; et al. The Interaction of Innate Immune and Adaptive Immune System. MedComm (2020) 2024, 5, e714, doi:10.1002/mco2.714. 76. Pashazadeh Azari, P.; Rezaei Zadeh Rukerd, M.; Charostad, J.; Bashash, D.; Farsiu, N.; Behzadi, S.; Mahdieh Khoshnazar, S.; Heydari, S.; Nakhaie, M. Monkeypox (Mpox) vs. Innate Immune Responses: Insights into Evasion Mechanisms and Potential Therapeutic Strategies. Cytokine 2024, 183, 156751, doi:10.1016/j.cyto.2024.156751. 77. Banjar, W.M.; Alaqeel, M.K. Monkeypox Stigma and Risk Communication; Understanding the Dilemma. Journal of Infection and Public Health 2024, 17, 4–7, doi:10.1016/j.jiph.2023.03.002. 78. Dahmana, H.; Granjon, L.; Diagne, C.; Davoust, B.; Fenollar, F.; Mediannikov, O. Rodents as Hosts of Pathogens and Related Zoonotic Disease Risk. Pathogens 2020, 9, 202, doi:10.3390/pathogens9030202. 79. Petersen, E.; Kantele, A.; Koopmans, M.; Asogun, D.; Yinka-Ogunleye, A.; Ihekweazu, C.; Zumla, A. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis Clin North Am 2019, 33, 1027–1043, doi:10.1016/j.idc.2019.03.001. 80. Grant, R.; Nguyen, L.-B.L.; Breban, R. Modelling Human-to-Human Transmission of Monkeypox. Bull World Health Organ 2020, 98, 638–640, doi:10.2471/BLT.19.242347. 81. Ahmed, S.K.; El-Kader, R.G.A.; Abdulqadir, S.O.; Abdullah, A.J.; El-Shall, N.A.; Chandran, D.; Dey, A.; Emran, T.B.; Dhama, K. Monkeypox Clinical Symptoms, Pathology, and Advances in Management and Treatment Options: An Update. Int J Surg 2023, 109, 2837–2840, doi:10.1097/JS9.0000000000000091. 82. Kang, J.H. Febrile Illness with Skin Rashes. Infect Chemother 2015, 47, 155–166, doi:10.3947/ic.2015.47.3.155. 83. Griffiths, E.C.; Pedersen, A.B.; Fenton, A.; Petchey, O.L. The Nature and Consequences of Coinfection in Humans. J Infect 2011, 63, 200–206, doi:10.1016/j.jinf.2011.06.005. 84. Gurnani, B.; Kaur, K.; Chaudhary, S.; Balakrishnan, H. Ophthalmic Manifestations of Monkeypox Infection. Indian Journal of Ophthalmology 2023, 71, 1687–1697, doi:10.4103/ijo.IJO_2032_22. 85. Gupta, A.K.; Talukder, M.; Rosen, T.; Piguet, V. Differential Diagnosis, Prevention, and Treatment of Mpox (Monkeypox): A Review for Dermatologists. Am J Clin Dermatol 2023, 24, 541–556, doi:10.1007/s40257-023-00778-4. 86. Patel, A.; Bilinska, J.; Tam, J.C.H.; Da Silva Fontoura, D.; Mason, C.Y.; Daunt, A.; Snell, L.B.; Murphy, J.; Potter, J.; Tuudah, C.; et al. Clinical Features and Novel Presentations of Human Monkeypox in a Central London Centre during the 2022 Outbreak: Descriptive Case Series. BMJ 2022, e072410, doi:10.1136/bmj-2022-072410. 87. Hwang, K.-A.; Ahn, J.H.; Nam, J.-H. Diagnosis of Viral Infection Using Real-Time Polymerase Chain Reaction. J Bacteriol Virol 2018, 48, 1, doi:10.4167/jbv.2018.48.1.1. 88. Hammarlund, E.; Lewis, M.W.; Carter, S.V.; Amanna, I.; Hansen, S.G.; Strelow, L.I.; Wong, S.W.; Yoshihara, P.; Hanifin, J.M.; Slifka, M.K. Multiple Diagnostic Techniques Identify Previously Vaccinated Individuals with Protective Immunity against Monkeypox. Nat Med 2005, 11, 1005–1011, doi:10.1038/nm1273. 89. Fox, T.; Geppert, J.; Dinnes, J.; Scandrett, K.; Bigio, J.; Sulis, G.; Hettiarachchi, D.; Mathangasinghe, Y.; Weeratunga, P.; Wickramasinghe, D.; et al. Antibody Tests for Identification of Current and Past Infection with SARS-CoV-2. Cochrane Database of Systematic Reviews 2022, 2022, doi:10.1002/14651858.CD013652.pub2. 90. Burrell, C.J.; Howard, C.R.; Murphy, F.A. Laboratory Diagnosis of Virus Diseases. In Fenner and White’s Medical Virology; Elsevier, 2017; pp. 135–154 ISBN 978-0-12-375156-0. 91. Mitjà, O.; Ogoina, D.; Titanji, B.K.; Galvan, C.; Muyembe, J.-J.; Marks, M.; Orkin, C.M. Monkeypox. The Lancet 2023, 401, 60–74, doi:10.1016/S0140-6736(22)02075-X. 92. Greenberg, R.N.; Hay, C.M.; Stapleton, J.T.; Marbury, T.C.; Wagner, E.; Kreitmeir, E.; Röesch, S.; Von Krempelhuber, A.; Young, P.; Nichols, R.; et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects. PLoS ONE 2016, 11, e0157335, doi:10.1371/journal.pone.0157335. 93. Fox, T.; Gould, S.; Princy, N.; Rowland, T.; Lutje, V.; Kuehn, R. Therapeutics for Treating Mpox in Humans. Cochrane Database of Systematic Reviews 2023, 2023, doi:10.1002/14651858.CD015769. 94. Mazurkov, O.Yu.; Kabanov, A.S.; Shishkina, L.N.; Sergeev, A.A.; Skarnovich, M.O.; Bormotov, N.I.; Skarnovich, M.A.; Ovchinnikova, A.S.; Titova, K.A.; Galahova, D.O.; et al. New Effective Chemically Synthesized Anti-Smallpox Compound NIOCH-14. Journal of General Virology 2016, 97, 1229–1239, doi:10.1099/jgv.0.000422. 95. Grabenstein, J.D.; Hacker, A. Vaccines against Mpox: MVA-BN and LC16m8. Expert Review of Vaccines 2024, 23, 796–811, doi:10.1080/14760584.2024.2397006. 96. Grabenstein, J.D.; Hacker, A. Vaccines against Mpox: MVA-BN and LC16m8. Expert Review of Vaccines 2024, 23, 796–811, doi:10.1080/14760584.2024.2397006. 97. Mucker, E.M.; Freyn, A.W.; Bixler, S.L.; Cizmeci, D.; Atyeo, C.; Earl, P.L.; Natarajan, H.; Santos, G.; Frey, T.R.; Levin, R.H.; et al. Comparison of Protection against Mpox Following mRNA or Modified Vaccinia Ankara Vaccination in Nonhuman Primates. Cell 2024, 187, 5540-5553.e10, doi:10.1016/j.cell.2024.08.043. 98. Russo, D.; Garcia-Gutierrez, J.V.; Soverini, S.; Baccarani, M. Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. JCM 2020, 9, 1709, doi:10.3390/jcm9061709. 99. De La Calle-Prieto, F.; Estébanez Muñoz, M.; Ramírez, G.; Díaz-Menéndez, M.; Velasco, M.; Azkune Galparsoro, H.; Salavert Lletí, M.; Mata Forte, T.; Blanco, J.L.; Mora-Rillo, M.; et al. Treatment and Prevention of Monkeypox. Enfermedades infecciosas y microbiologia clinica (English ed.) 2023, 41, 629–634, doi:10.1016/j.eimce.2022.12.010. 100. Yong, S.E.F.; Ng, O.T.; Ho, Z.J.M.; Mak, T.M.; Marimuthu, K.; Vasoo, S.; Yeo, T.W.; Ng, Y.K.; Cui, L.; Ferdous, Z.; et al. Imported Monkeypox, Singapore. Emerg. Infect. Dis. 2020, 26, 1826–1830, doi:10.3201/eid2608.191387. 101. Imran, Mohd.; Alshammari, M.K.; Arora, M.K.; Dubey, A.K.; Das, S.S.; Kamal, M.; Alqahtani, A.S.A.; Sahloly, M.A.Y.; Alshammari, A.H.; Alhomam, H.M.; et al. Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects. Biomedicines 2023, 11, 278, doi:10.3390/biomedicines11020278. 102. Philippidis, A. StockWatch: Novavax Hits 52-Week Low as Rivals Win FDA Omicron Booster OKs: Jounce Falls on Clinical Setback; Liquidia Rises on Patent Rulings; Chimerix Soars on BARDA Contract; Smaller IPO Scores for Shuttle Pharma. GEN Edge 2022, 4, 660–665, doi:10.1089/genedge.4.1.108. 103. De Clercq, E.; Jiang, Y.; Li, G. Therapeutic Strategies for Human Poxvirus Infections: Monkeypox (Mpox), Smallpox, Molluscipox, and Orf. Travel Medicine and Infectious Disease 2023, 52, 102528, doi:10.1016/j.tmaid.2022.102528. 104. Quarleri, J.; Delpino, M.V.; Galvan, V. Monkeypox: Considerations for the Understanding and Containment of the Current Outbreak in Non-Endemic Countries. GeroScience 2022, 44, 2095–2103, doi:10.1007/s11357-022-00611-6. 105. Comerford, I.; McColl, S.R. Atypical Chemokine Receptors in the Immune System. Nat Rev Immunol 2024, 24, 753–769, doi:10.1038/s41577-024-01025-5. 106. Siendones, E.; SantaCruz-Calvo, S.; Martín-Montalvo, A.; Cascajo, M.V.; Ariza, J.; López-Lluch, G.; Villalba, J.M.; Acquaviva-Bourdain, C.; Roze, E.; Bernier, M.; et al. Membrane-Bound CYB5R3 Is a Common Effector of Nutritional and Oxidative Stress Response Through FOXO3a and Nrf2. Antioxidants & Redox Signaling 2014, 21, 1708–1725, doi:10.1089/ars.2013.5479. 107. Adamo, S.; Gao, Y.; Sekine, T.; Mily, A.; Wu, J.; Storgärd, E.; Westergren, V.; Filén, F.; Treutiger, C.-J.; Sandberg, J.K.; et al. Memory Profiles Distinguish Cross-Reactive and Virus-Specific T Cell Immunity to Mpox. Cell Host & Microbe 2023, 31, 928-936.e4, doi:10.1016/j.chom.2023.04.015. 108. Xu, T.; Chen, Z.; Zhou, X.; Wang, L.; Zhou, F.; Yao, D.; Zhou, B.; Becker, B. The Central Renin–Angiotensin System: A Genetic Pathway, Functional Decoding, and Selective Target Engagement Characterization in Humans. Proc. Natl. Acad. Sci. U.S.A. 2024, 121, e2306936121, doi:10.1073/pnas.2306936121. 109. International MHC and Autoimmunity Genetics Network (IMAGEN)*; Rioux, J.D.; Goyette, P.; Vyse, T.J.; Hammarström, L.; Fernando, M.M.A.; Green, T.; De Jager, P.L.; Foisy, S.; Wang, J.; et al. Mapping of Multiple Susceptibility Variants within the MHC Region for 7 Immune-Mediated Diseases. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 18680–18685, doi:10.1073/pnas.0909307106. 110. Chakravarty, N.; Hemani, D.; Paravastu, R.; Ahmad, Z.; Palani, S.N.; Arumugaswami, V.; Kumar, A. Mpox Virus and Its Ocular Surface Manifestations. The Ocular Surface 2024, 34, 108–121, doi:10.1016/j.jtos.2024.07.001. 111. Parnian, R.; Heydarifard, F.; Mousavi, F.S.; Heydarifard, Z.; Zandi, M. Innate Immune Response to MPOX Infection: Mechanisms and Immune Escape. J Innate Immun 2024, doi:10.1159/000540815. 112. Schmidt, N.; Domingues, P.; Golebiowski, F.; Patzina, C.; Tatham, M.H.; Hay, R.T.; Hale, B.G. An Influenza Virus-Triggered SUMO Switch Orchestrates Co-Opted Endogenous Retroviruses to Stimulate Host Antiviral Immunity. Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 17399–17408, doi:10.1073/pnas.1907031116.

Regular Issue Subscription Review Article
Volume 03
Issue 01
Received 31/01/2026
Accepted 04/02/2026
Published 20/02/2026
Publication Time 20 Days
81

Login


My IP

PlumX Metrics